http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
-
Champions Oncology Obtains Radioactive Materials License to Advance Comprehensive Radiotherapeutic Studies In-House
-
Champions Oncology to Announce Third Quarter Financial Results on Tuesday, March 11, 2025
-
Champions Oncology Announces 17 Abstracts Accepted for Presentation at the 2025 American Association for Cancer Research Annual Meeting
-
Champions Oncology (CSBR) Enhances Clinical Bioanalytical Services Portfolio with New Technology and Additional Leadership
-
Champions Oncology Enhances Clinical Bioanalytical Services Portfolio with New Technology and Additional Leadership
-
Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Thursday, July 18, 2024
-
Champions Oncology and Medicines Discovery Catapult Forge Partnership to Accelerate Radiopharmaceutical Therapeutics Development
-
Champions Oncology's US Laboratory has Acquired Distinguished CAP Accreditation
-
Champions Oncology erhält für seinen europäischen Forschungsstandort eine ISO-9001:2015-Akkreditierung und ATS-Zertifizierung
-
Champions Oncology's European Research Operations Site Receives ISO-9001:2015 Accreditation and ATS Certification
-
Champions Oncology (CSBR) Appoints Brady Davis as President
-
Champions Oncology Announces the Addition of Brady Davis as President
-
Champions Oncology Aannounces Remarkable Lineup of Speakers at Its Translational Oncology Symposium in Boston in September 2023
-
Champions Oncology (CSBR) Enters Multi-Year Agreement and Strategic Collaboration with BioVolume to Transform Reproducibility in Preclinical Oncology Efficacy Studies
-
Champions Oncology Announces a Multi-Year Agreement and Strategic Collaboration with BioVolume to Transform Reproducibility in Preclinical Oncology Efficacy Studies
-
Champions Oncology Announces the Formation of Corellia AI, a Wholly Owned Biotech that Leverages Unique AI-Enabled Workflows for Novel Therapeutic Development
-
Champions Oncology Announces a Partnership with Cyclica to Develop Small Molecule Therapeutics
-
Champions Oncology Announces its Lumin Bioinformatics Platform Selected as a Finalist for the 'Best in Show' Competition at Bio-IT World Conference & Expo
-
Champions Oncology Announces a Partnership with GigaMune to Discover Novel Tumor-Reactive T Cell Receptors
-
Champions Oncology (CSBR) Enters Partnership with Fannin Innovation to Develop Therapeutic Raptamer Drug Conjugates
-
Champions Oncology Announces a Partnership with Fannin Innovation to Jointly Develop Therapeutic Raptamer Drug Conjugates
-
Champions Oncology Announces a Partnership with Alloy Therapeutics to Develop Therapeutic Monoclonal Antibodies for Use in ADC Programs
-
Champions Oncology Announces an Expanded Corporate Strategy to Include Drug Discovery and Development
-
Champions Oncology Announces Partnership with Code Ocean to Expand the Functionality of Lumin Bioinformatics
-
Champions Oncology Announces the Launch of Lumin Bioinformatics, Its New Oncology Data-Driven SaaS Program
-
Champions Oncology Expands Its Immuno-Oncology Research Offering by Launching a Unique Autologous Tumor Infiltrating Lymphocyte Ex Vivo Platform
-
The Children's Cancer Therapy Development Institute is collaborating with Champions Oncology and The Jackson Laboratory to provide RACE Act/PREA pediatric cancer study plan services
-
Champions Oncology, Inc. (Nasdaq: CSBR) to Ring The Nasdaq Stock Market Closing Bell
-
Champions Oncology, Inc. (Nasdaq: CSBR) to Ring The Nasdaq Stock Market Closing Bell

